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Identification, Cloning, and Mutational Analysis of the Casein
Kinase 1 cDNA of the Malaria Parasite, Plasmodium falciparum
STAGE-SPECIFIC EXPRESSION OF THE GENE*
(Received for publication, April 15, 1997, and in revised form, July 28, 1997)
Sailen Barik‡§, Russell E. Taylor‡, and Debopam Chakrabarti¶
From the ‡Department of Biochemistry and Molecular Biology, University of South Alabama, Mobile, Alabama 36688
and the ¶Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida 32816
The cDNA for casein kinase 1 (CK1) of Plasmodium
falciparum was cloned, sequenced, and expressed in
bacteria. The single major open reading frame of the
1.2-kilobase pair cDNA coded for a 324-amino acid
polypeptide of ;37 kDa, the predicted sequence of
which showed strong identity with known CK1 isoforms.
The purified recombinant enzyme exhibited properties
characteristic of CK1, such as inhibition by CK1–7, the
ability to phosphorylate a highly specific peptide sub-
strate, and a strong preference for ATP over GTP. A
casein kinase activity, partially purified from soluble
extracts of P. falciparum by affinity chromatography
through CK1–7 columns displayed identical properties.
The activity showed a stage-specific expression in the
parasite, in the order trophozoite > ring >> schizont.
Northern analysis indicated the existence of two major
CK1 mRNAs, 2.4 and 3.2 kilobase pairs long, the levels of
which were in the order ring > schizont > trophozoite.
Mutagenesis of recombinant CK1 defined important
amino acid residues and their potential role in the con-
formation of the enzyme. The malarial CK1 appeared to
be the one of the smallest and perhaps the most primi-
tive CK1 enzymes known, containing little sequence in-
formation beyond the minimal catalytic domain.
The parasitic protozoan, Plasmodium falciparum, is the
causative agent of malaria throughout the world and is respon-
sible for an annual death toll of nearly 3 million, the majority
of which are children and pregnant mothers (1). However, tools
available to control malaria are inadequate, and drug-resistant
strains are widespread; moreover, the immediate prospect of a
useful vaccine is uncertain. Thus, there is an urgent need to
obtain fundamental knowledge about the various cellular pro-
cesses of P. falciparum at the molecular level, so that suscep-
tible targets can be identified. With this long-term goal in
mind, we have initiated studies of the signal transduction
system in P. falciparum. Since reversible protein phosphoryl-
ation and dephosphorylation constitute a major mechanism of
signal transduction (2), one of our immediate goals has been to
characterize the various protein kinases in P. falciparum. In
this paper, we report the characterization, expression, stage-
specific regulation, and mutational analysis of P. falciparum
casein kinase 1 (PfCK1).1
Casein kinase-1 and -2 (CK1 and CK2) are multipotential
Ser/Thr protein kinases, originally purified from rabbit reticu-
locyte lysates using casein as substrate (reviewed in Refs. 3 and
4). In the subsequent years, both enzymes were shown to phos-
phorylate, and thus regulate, a wide variety of cellular pro-
teins. The sequence alignment of CK1 genes of various organ-
isms and deletion analysis of recombinant yeast CK1 have
recently resulted in the delineation of the following domains in
the prototype 45-kDa yeast enzyme (summarized in Refs. 5 and
6): an N-terminal catalytic domain of about 300 amino acids
followed by a 12-residue stretch conserved among some forms
but not in others; a hydrophilic 85-residue segment predicted to
be flexible and rich in Pro and Ser; and finally, a 43-residue-
long C-terminal prenylation site that contains the localization
signal. The crystal structure of the 298-residue catalytic core of
the Schizosaccharomyces pombe CK1 in complex with MgATP
has recently been elucidated at 2.0-Å resolution (6). The struc-
ture suggested the roles of a number of conserved residues in
various catalytic functions of the enzyme, such as binding of
ATP, Mg21, and the phosphate groups of the substrate.
To confirm the identity of the malarial CK1 (PfCK1) cDNA,
we have studied the biochemical properties of the recombinant
malarial enzyme in detail and compared them with the native
enzyme activity. In addition, preliminary mutational analysis
of the enzyme was carried out to ascertain the essential nature
of some of the invariant residues and their effect on the enzy-
matic parameters. Studies of stage-specific expression of the
PfCK1 gene suggested transcriptional as well as post-tran-
scriptional regulations. Our results constitute the first report
of a CK1 enzyme in an eukaryotic protozoan parasite.
EXPERIMENTAL PROCEDURES
Parasite Culture and Extract—P. falciparum strain Dd2 was main-
tained in a modified erythrocyte culture (7, 8). Cultures were synchro-
nized by purification of schizont stage over 65% Percoll (Pharmacia)
cushion followed by incubation of ring stage parasites in 5% D-sorbitol
(9). 1 liter of a synchronous P. falciparum culture of appropriate stage
and at a parasitemia of 15–20% was treated with saponin (0.1% final
concentration) to lyse erythrocytes. The parasite pellet was resus-
pended in the lysis buffer (50 mM Tris-Cl, pH 7.6, 2 mM dithiothreitol,
2 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin,
1% (v/v) aprotinin), homogenized, and briefly sonicated at 4 °C. The
lysate was centrifuged at 100,000 3 g for 1 h at 4 °C. The supernatant
(S100) was subjected to ammonium sulfate precipitation (0–60%) fol-
lowed by resuspension and dialysis of the pellet fraction in the above
buffer.
Isolation of P. falciparum genomic DNA and RNA from Saponin-
* The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact. A preliminary account of this work was presented at
the Molecular Parasitology Meeting VII in Woods Hole, MA (September
15–19, 1996).
The nucleotide sequence(s) reported in this paper has been submitted
to the GenBankTM/EBI Data Bank with accession number(s)
AF017139.
§ To whom correspondence should be addressed. Tel.: 334-460-6860;
Fax: 334-460-6127; E-mail: sbarik@jaguar1.usouthal.edu.
1 The abbreviations used are: PfCK1, P. falciparum casein kinase 1;
CK1 and CK2, casein kinase-1 and -2, respectively; kb, kilobase pair;
PAGE, polyacrylamide gel electrophoresis.
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lysed P. falciparum-infected erythrocytes and cloning of the cDNA into
pBlueScript have been described (10).
Expression of the Malarial CK1 Gene in Bacteria—The putative
PfCK1 gene open reading frame (975 base pairs) was subcloned from
pBlueScript-SK6 to the T7-based bacterial expression plasmid pET3a
as follows. The gene was amplified by the following primers (corre-
sponding to the 59- and 39-ends of the gene, respectively): 59-GGAGTT-
GCATATGGAAATTAGAGTGGCA-39 and 59-GAGGATCCATCAATTA-
TTTCGTTGATCTC-39 (the NdeI and BamHI sites are underlined). The
PCR product was restricted with NdeI and BamHI and cloned into the
same two sites of pET3a or pET15b as described (11). The resulting
clones, designated pET3a-PfCK1 or pET15b-PfCK1, were confirmed by
DNA sequencing and introduced into E. coli BL21(DE3). Growth of the
transformant, induction with isopropyl-1-thio-b-D-galactopyranoside,
and lysis with lysozyme-EDTA were carried out essentially as described
previously (11). SDS-PAGE were performed according to Laemmli (12),
using a 14% acrylamide (acrylamide:bisacrylamide 5 30:0.4) gel for
proteins and a 40% gel for peptides.
Site-directed mutagenesis and deletion of the cloned CK1 gene was
performed by the PCR-based “megaprimer” method as described previ-
ously (13).
Purification of Recombinant PfCK1—The total extract of 1 g of in-
duced BL21(DE3) cells containing the pET3a-PfCK1 plasmid was pre-
pared as above and sonicated to shear the chromosomal DNA and
reduce viscosity (5). The lysate was centrifuged at 120,000 3 g, and the
supernatant (S100) containing soluble recombinant CK1 was loaded on
an 8-ml DEAE-cellulose column equilibrated with buffer A (50 mM
Tris-Cl, pH 7.5, 0.1 mM EDTA, 5% glycerol, 1 mM dithiothreitol) con-
taining 20 mM NaCl. Using a NaCl gradient in buffer A, the enzyme was
subsequently eluted at an NaCl concentration of about 80 mM. The
pooled fractions were directly applied to a 5-ml phosphocellulose col-
umn equilibrated with buffer A plus 80 mM NaCl and then eluted at
about 0.5 M NaCl in a salt gradient. The phosphocellulose fraction,
already highly pure (Fig. 8, lane 1), was concentrated by filtration
through a Centricon-10 cartridge and further purified by a gel filtration
chromatography through Sephadex G-50 (Fig. 8, lane 2), from which it
eluted as an apparent monomer (data not shown).
Polyhistidine-tagged CK1 and its mutants (from the pET15b-PfCK1
clone) were purified essentially as described (5). For comparison, puri-
fied recombinant CK1d subunit, expressed in Escherichia coli (14), was
purchased from New England Biolabs (Bedford, MA).
Affinity Chromatography of CK1—Sepharose coupled to the iso-
quinolinesulfonamide compound CK1–7 (Seikagaku America, Ijaxville,
MD), a specific CK1 inhibitor, was generated by reacting 5 mg of CK1–7
with 0.5 ml of CNBr-activated Sepharose 4B following standard proce-
dures. Affinity chromatography of CK1 enzyme on this column was
performed essentially as suggested (15), with some modifications as
follows. 0.1 ml (1.0 mg of protein) of malarial S100 extract was passed
four times through the CK1–7 column. The column was washed first
with 1 ml of buffer B containing 1 mM dithiothreitol and then with 0.5
ml of 0.2 M arginine. The bound CK1 was eluted with 0.3 ml of 0.8 M
arginine (15). The eluate was dialyzed overnight against buffer B con-
taining 5 mM b-mercaptoethanol and stored frozen at 280 °C.
Casein Kinase Assay—Unless otherwise mentioned, standard protein
kinase assay reactions (10 ml) contained the following: 20 mg a-casein
(not dephosphorylated; from Sigma) or 1 mM of the synthetic peptide
KRRRALpSVASLPGL (where pS represents phosphoserine) (New Eng-
land Biolabs), 15 mM (10 mCi) [g-32P]ATP (or [g-32P]GTP of same specific
activity, where mentioned), 10 mM MgCl2, 1 mM dithiothreitol, and
50–100 ng of purified kinase in buffer B (50 mM Tris-Cl, pH 7.5, 120 mM
NaCl, 5% glycerol). Where indicated, heparin or CK1–7 was also in-
cluded in the reaction. 10 mM stock solutions of CK1–7 were made in
Me2SO, from which appropriate dilutions were made in water immedi-
ately before use. Reactions were initiated by the addition of the kinase
and incubated for 15 min at 37 °C. When the synthetic peptide was the
substrate, 2–4 ml of the reaction was stopped by the addition of SDS-
sample buffer, boiled for 5 min, and analyzed by electrophoresis in 40%
polyacrylamide gels containing SDS (16), followed by autoradiography.
Where needed, the autoradiographs were scanned densitometrically.
When casein was used as substrate, 32P incorporation was quantitated
by trichloroacetic acid precipitation on Whatman 31-ET paper (17). One
unit of casein kinase was defined as the activity capable of incorporat-
ing 1 nmol of phosphate to casein in 1 h at 37 °C. The catalytic param-
eters (Vmax, Kcat, and Km) were measured under standard assay condi-
tions and calculated by the Eadie-Hofstee method (18, 19). Km of casein
was calculated on the basis of its assumed molecular mass of 24 kDa.
Casein kinase 2 (CK2) reactions were performed under identical condi-
tions using recombinant CK2 (11).
RESULTS
Identification of the CK1 cDNA Homolog in the Malaria
Parasite—Sequencing of random clones from a P. falciparum
cDNA library in the Malaria Parasite Gene Sequencing Project
(20) identified a clone with a 1.3-kb insert, which displayed
significant homology to CK1 sequences in the National Center
for Biotechnology Information data base. This putative CK1
gene, designated the PfCK1 gene, contained a 975-nucleotide-
long open reading frame with the potential to code for a
polypeptide of 324 amino acids. The 39-untranslated sequence
of PfCK1 was 190 nucleotides long, followed by a poly(A) tail.
The deduced sequence of PfCK1 polypeptide showed extensive
similarity with the N-terminal catalytic region of known CK1
polypeptides. A representative comparison with human and
yeast CK1 is shown in Fig. 1. PfCK1 protein was found to be
59% similar to the human sequence; the similarity increased to
69% if conservative replacements were also included. Of par-
ticular significance was the finding that PfCK1 contained es-
sentially all of the amino acid residues that were completely
invariant in all known CK1 proteins (Fig. 1, asterisks). The
seven PfCK1 residues that were exceptions to this are indi-
cated by dots above them (Fig. 1); three of these were noncon-
servative replacements, viz. Thr78, Tyr165, and Ser245, the cor-
responding invariant residues in all other CK1s being Asn, Ile,
and Pro, respectively. Since the malarial CK1 was catalytically
active (see below), we can conclude that these three residues
may not be important in catalysis.
Organization of the PfCK1 Gene—To gather a preliminary
knowledge of the PfCK1 gene organization, we carried out a
Southern blot analysis of restriction endonuclease-digested P.
falciparum genomic DNA using 32P-labeled PfCK1 cDNA in-
sert as probe. As shown in Fig. 2A, the majority of the restric-
tion enzymes produced a single band, suggesting the existence
of a single CK1 gene. RNA blot (Northern) analysis (Fig. 2B)
revealed the existence of two size classes of transcripts, viz. 2.4
and 3.2 kb. Since the combined length of the PfCK1 coding
sequence and the 39-untranslated sequence is 1.17 kb, the
59-untranslated sequence appears to be at least 1.2 kb in
length. This rather long 59-untranslated sequence is typical of
many malaria parasite transcripts (10). It remains to be deter-
mined whether the two transcripts are due to different tran-
scription events or are products of alternate splicing.
Characterization of CK1 Activity of the Malaria Parasite—To
identify CK1 activity in P. falciparum, we subjected its S100
extract to affinity chromatography using the isoquinolinesul-
fonamide compound, CK1–7 (15). A malarial protein fraction
obtained in this manner exhibited a potent casein kinase ac-
tivity (Fig. 3) that was resistant to heparin (90% activity with
25 mg/ml heparin) but sensitive to CK1–7 (66 and 85% inhibi-
tion with 10 mM and 20 mM CK1–7, respectively).
The native malarial CK1 fraction also efficiently phosphoryl-
ated the CK1-specific peptide substrate, KRRRALpS-
VASLPGL, where the underlined Ser is the CK1 phosphoryla-
tion site (Fig. 4). 40 mM CK1–7 inhibited phosphorylation by
nearly 80% at an ATP concentration of 15 mM (lane 4). The
recombinant CK1d isoform of rat testis expressed in E. coli (22)
exhibited an essentially similar inhibition by CK1–7 (lane 2).
Interestingly, heparin (10 mg/ml) stimulated the activity about
2-fold. As discussed later, the unique stimulatory effect of hep-
arin, observed only when a small peptide was used as sub-
strate, was also demonstrated with the CK1d isoform (17). The
enzyme demonstrated a marked preference for ATP; GTP was
used much less efficiently (Fig. 4, lane 6). Together, these
results demonstrate that P. falciparum contains a protein ki-
nase activity essentially identical to CK1.
Stage-specific Expression of PfCK1 mRNA and Enzyme—The
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malaria parasite undergoes distinct morphological changes
during the progression through its intraerythrocytic life cycle:
rings (initial maturation stage following invasion), trophozoites
(larger mononucleated metabolically active cells containing he-
mozoin pigment), and schizonts (multinucleated cells). To ad-
dress whether the PfCK1 gene is expressed in a stage-specific
manner through this intricate life cycle, RNA samples were
isolated from synchronized cultures every 6 h. As shown by Fig.
5, the expression of PfCK1 transcripts is indeed cell cycle-
regulated. Both size classes of transcript showed a peak expres-
sion in the early ring stage and were barely detectable in
trophozoite and schizont stages.
Interestingly, when we determined the specific activity of
CK1 in the S100 extracts of the various stages of the parasite,
a different picture emerged. Using the specific phosphopeptide
substrate, the highest CK1 activity was found in trophozoites,
followed by rings, while the activity in the schizonts was barely
detectable (Fig. 6). The relative activities in the three stages,
determined by densitometric scanning, were in the ratio 100:
42:3. The authenticity of the CK1 activity was further verified
by its sensitivity to the inhibitor CK1–7 and by comparison to
CK1d (Fig. 6). At 20 mM CK1–7, for example, activities of all
stages were inhibited by 85–90%.
Endogenous Substrates of Malarial CK1—In an attempt to
obtain a preliminary estimate of the natural substrates of the
malarial CK1, we subjected the S100 extracts of the three
major stages of the parasite to self-phosphorylation, whereby
equal amounts of the S100 proteins were incubated in the
presence of [g-32P]ATP and increasing concentrations of
CK1–7. Analysis of the reaction products on SDS-PAGE, as
shown in Fig. 7, led to a number of findings, summarized as
follows. (a) A number of malarial polypeptides appeared to
serve as substrates for endogenous kinases. The major phos-
phoprotein species common in both rings and trophozoites ex-
hibited molecular masses of 66, 60, 33, and 27 kDa in addition
to a number of high molecular weight species, whereas the 42-
FIG. 1. Amino acid sequence align-
ment of CK1 polypeptides. The pre-
dicted amino acid sequences of the malar-
ial, human (21), and yeast (S. pombe; Ref.
22) CK1 polypeptides have been com-
pared using the PILEUP and PRETTY
programs of the Genetics Computer
Group package (Madison, WI). The num-
berings are based on the malarial se-
quence. Asterisks denote amino acid resi-
dues that are invariant in all known CK1
isoforms identified to date; the malarial
residues that are exceptions to this rule
are indicated by dots above the residues.
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and 36-kDa species were predominant in rings only. The schiz-
onts, on the other hand, exhibited a pattern that is very differ-
ent from either rings or trophozoites and consisted of two major
species of about 98 and 75 kDa. In all three extracts, most of
the phosphoproteins appeared to be minor Plasmodium S100
proteins, as judged by comparing the bands in the autoradio-
gram with those in the corresponding Coomassie Blue-stained
gel (panel A). (b) With increasing concentrations of CK1–7,
phosphorylated bands of both ring and trophozoites started to
disappear much earlier than those of the schizont. At 50 mM
CK1–7, for example, phosphorylation of ring and trophozoite
extracts was almost completely inhibited, whereas that of schi-
zonts remained substantially unaffected. Together, these re-
sults suggest that CK1 may be a major protein kinase in the
ring and trophozoite stages, while the schizont stage may have
a different kinase make-up. (c) In an effort to assess whether
the stage-specific phosphoprotein pattern was due to a differ-
ence in the level of substrates or enzymes, purified recombi-
nant malarial CK1 was added to extracts of all three stages
(Fig. 7, lanes with plus sign). Interestingly, this restored the
schizont pattern to resemble those of ring and trophozoite,
while the patterns of the latter two stages remained virtually
unaltered. As expected, only those bands in the schizont ex-
tracts that were due to the exogenously added CK1 exhibited
sensitivity to CK1–7. These results strongly suggest that schi-
zonts are substantially devoid of CK1 activity rather than CK1
substrates.
Enzymatic Activity of Bacterially Expressed Malarial CK1—
Upon induction of BL21(DE3) containing pET3a-PfCK1 with
isopropyl-1-thio-b-D-galactopyranoside, a polypeptide of Mr
;37,000 was produced (Fig. 8), which is in reasonable agree-
ment with the predicted molecular weight of 37,807 for the CK1
open reading frame polypeptide, considering the slight overall
basicity of the predicted polypeptide (42 Asp and Glu residues;
55 Lys and Arg residues). The 37-kDa protein was purified by
chromatography through DEAE and phosphocellulose and then
by gel filtration using Sephadex G50. During purification, the
casein kinase activity always co-chromatographed with the
37-kDa polypeptide. The final preparation (Fig. 8, lane 2) was
at least 90% pure, with no single contaminant constituting
more than 5% of the 37-kDa polypeptide. In vitro, the purified
recombinant enzyme efficiently phosphorylated casein (Fig. 9)
with a specific activity of ;1020 units/mg of protein. The activ-
ity was resistant to heparin (25 mg/ml) but was inhibited by
about 70 and 80% in the presence of 10 and 20 mM CK1–7,
respectively (Fig. 9). Under the same reaction conditions, pu-
rified CK2 was inhibited by heparin but retained about 90 and
FIG. 2. A, Southern analysis of P. falciparum Dd2 genomic DNA. 3 mg
of genomic DNA, restricted with the following enzymes, was subjected
to Southern analysis using PfCK1 cDNA as probe (10). Lane 1, NdeI;
lane 2, PstI; lane 3, EcoRI; lane 4, EcoRV; lane 5, BamHI; lane 6,
HindIII; lane 7, XbaI; lane 8, KpnI. B, Northern analysis of CK1 RNA.
10 mg of total P. falciparum RNA from asynchronous culture was probed
with PfCK1 cDNA (10). Standard DNA and RNA markers are shown.
FIG. 3. Casein kinase activity of native PfCK1. Approximately 20
ng of malarial enzyme fraction purified by affinity chromatography
through a CK1–7 column was tested for casein kinase activity in stand-
ard phosphorylation reactions, followed by analysis in SDS-PAGE.
Lane M represents a stained lane containing casein; others lanes are
autoradiographs. Phosphorylation reactions were carried out with the
following additions: none (lane 1); 25 mg/ml heparin (lane 2); 10 mM
CK1–7 (lane 3); and 20 mM CK1–7 (lane 4). Lane 0 is a control (no
enzyme).
FIG. 4. Activity of native PfCK1 on a specific peptide sub-
strate. Phosphorylation of the peptide KRRRALpSVASLPGL by 20 ng
of native (CK1–7 affinity-purified) malarial CK1 (lanes 3–6) or by
commercial CK1 (lanes 1 and 2) and analysis of the reactions by SDS-
PAGE followed by autoradiography were carried out as described under
“Experimental Procedures.” Phosphate donors were [g-32P]ATP (lanes
0–5) or [g-32P]GTP (lane 6). The additions to the phosphorylation reac-
tions were as follows: none (lanes 1, 3, and 6); 40 mM CK1–7 (lanes 2 and
4); 10 mg/ml heparin (lane 5).
FIG. 5. Stage-specific expression of the PfCK1 mRNA. Total
RNA was isolated every 6 h from a synchronous P. falciparum Dd2
culture. Approximately 4 mg of RNA sample from each time point was
analyzed as in Fig. 2B. Lane 1, early trophozoite; lane 2, trophozoite;
lane 3, mature trophozoite/early schizont; lane 4, schizont; lane 5,
segmented; lane 6, early ring; lane 7, ring. Positions of standard RNA
markers (in kb) are shown. The relative amounts of the transcripts,
determined by densitometric scanning of the autoradiograph, are in the
following ratio (left to right): 4:14:12:22:45:100:98.
FIG. 6. Stage-specific PfCK1 activity. Peptide phosphorylation as-
says were carried out exactly as described in the Fig. 4 legend using 4
mg of stage-specific extracts (ring (R); trophozoite (T); schizont (S)),
prepared as described under “Experimental Procedures.” Numbers on
the top indicate CK1–7 concentrations (mM) used in the reaction. Lane
C is a reaction without any kinase; lanes marked CK1 represent reac-
tions with commercial CK1d.
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70% activity in the presence of 10 and 20 mM CK1–7, respec-
tively (3, 14). Thus, the recombinant malarial CK1 fraction
exhibited properties characteristic of the authentic CK1 class
of enzymes. The catalytic parameters, measured in the pres-
ence of 15 mM ATP and 2 mg casein per ml were as follows: Vmax,
17.5 6 1.5 mmol of casein/mg of enzyme/min; Kcat, 15.5 6 1.2
s21; Km (casein), 110 6 10 mM, producing a Kcat:Km ratio of 8.45
mM21 min21.
In an attempt to simplify the purification procedure and to
be able to rapidly screen various mutants of CK1 in the fu-
ture, we have also cloned PfCK1 into pET15b. This resulted
in the fusion of the 2-kDa histidine-rich peptide
MGSS(H)6SSGLVPRGSH to CK1, which increased the Mr of
the recombinant protein to about 39 kDa. The fusion protein
could be purified to near homogeneity in a single step using a
nickel column (Fig. 8, lane 3), and exhibited a specific activity
essentially identical to that of the nonfusion recombinant (data
not shown).
Mutational Analysis of Recombinant Malarial CK1—The
peptide stretch GXGXXG (residues 16–21), followed by a Lys38
16 residues downstream, is conserved in all CK1 catalytic cores
and is considered to be involved in ATP binding (23). Crystal-
lographic studies have suggested that the triphosphate moiety
of ATP interacts with three charged residues of CK1, viz.,
Lys38, Lys130, and Asp151 and with the amide backbone of Gly21
(6). In addition, Asn133 has been implicated in the coordination
of the single Mg12 ion in CK1. However, no detailed mutational
studies to validate these predictions have been performed. In
an earlier report, the K38N mutant was reported to be “kinase-
dead,” although the exact mechanism of the defect was not
studied (14). Since the malarial recombinant CK1 was enzy-
matically active, it gave us an opportunity to analyze the roles
of specific residues by site-directed mutagenesis. Our initial
studies employed His fusion PfCK1 mutants G21A and K38L
expressed in pET-15b (Fig. 8, lanes 4 and 5). In standard casein
kinase assays, both mutants were found to be highly defective.
For detailed kinetic studies, however, we expressed these and
other mutants in the pET-3a vector, free of any exogenous
sequences. Kinetic data presented in Table I revealed that the
K38L, K130L, and D151N mutants all had a highly elevated
Km for ATP and similarly defective Kcat. Interestingly, these
mutants also exhibited a higher Km for Mg
21, which supports
the notion that Mg21 binds ATP, and that the Mg21-ATP
complex is coordinated to the relevant residues of CK1. This is
further confirmed by the reciprocal mutation N133A, which not
only increased the Km for Mg
21 as expected but also had a
severe effect on the Km for ATP. Substitution of Gly
21 with
alanine had the least effect on enzymatic parameters, probably
because the two amino acids are very similar and the peptide
bond of Gly21 rather than its side chain is postulated to interact
with ATP (6).
The minimal length of a functional CK1 enzyme remains
undefined. Truncation of the C-terminal 148 amino acids of the
recombinant CKi1 of S. pombe (product of the cki1 gene) gen-
erated a 298-residue core that contained only 3 residues beyond
the invariant DW dipeptide (5). This “catalytic core” was enzy-
matically active and, as mentioned earlier, led to the only
crystal structure of CK1 available to date (6). However, larger
deletions of this or any other isoform of CK1 have not been
reported. To delineate the minimal length of the CK1 catalytic
core, we have carried out terminal deletions of the malarial
enzyme in the recombinant pET-3a clone. The truncated mu-
tants were expressed in bacteria, purified, and assayed using
casein as substrate. Deletion of 18 amino acid residues from the
FIG. 7. Endogenous phosphorylation of P. falciparum ex-
tracts. 5 mg of cytosolic extracts of ring (R), trophozoite (T), and schiz-
ont (S) stages of Plasmodium were self-phosphorylated in a standard
kinase reaction using [g-32P]ATP without any exogenous substrate. The
reactions were analyzed in SDS-PAGE and autoradiographed (panel B).
Panel A represents stained gel containing 80 mg of each extract as
indicated. Numbers on the left indicate sizes of protein markers (kDa);
numbers on top indicate CK1–7 concentrations (mM) included in the
reaction. The plus signs indicate reactions in which an additional 50 ng
of purified recombinant PfCK1 was added to the extracts. Major phos-
phoprotein bands are marked as follows according to their presence in
the extracts: both ring and trophozoites (single dots); rings only (double
dots); schizont-specific (arrowheads).
FIG. 8. Expression of recombinant PfCK1 in E. coli. Malarial
CK1 or its His fusion derivatives were cloned and expressed in pET3a
or pET15b, respectively, as described under “Experimental Proce-
dures.” BL21(DE3) cells containing the following recombinant CK1
clones were induced with isopropyl-1-thio-b-D-galactopyranoside (2
lane; or uninduced, 1 lane), and total extracts (2 and 1 lanes) or
purified fractions (lane 1, phosphocellulose fraction; lane 2, Sephadex
G-50 fraction) were analyzed on SDS-PAGE followed by staining with
Coomassie Blue: wild type CK1 (lanes 1, 2, 1, and 2); purified poly-
His-tagged wild type (lane 3); G21A mutant (lane 4); K38L mutant (lane
5), and the C-terminal D18 mutant (lane 6; see text for details). Lane M
represents protein standards in kDa. The CK1 bands are indicated by
arrowheads.
FIG. 9. Phosphorylation of casein by recombinant PfCK1. Ca-
sein was phosphorylated by purified recombinant malarial CK1 (CKI)
or by control CK2 (CKII) in standard phosphorylation reactions using
[g-32P]ATP as phosphate donor. The reactions were analyzed by SDS-
PAGE, followed by staining and autoradiography. Panel B shows the
autoradiograph, and panel A shows a representative stained portion of
the gel (M, 20-kDa standard; S, casein). Phosphorylation reactions were
carried out in the presence of the following: no additions (lanes 1 and 7);
25 mg/ml heparin (lanes 2 and 8); CK1–7, 10 mM (lanes 3 and 9), and 20
mM (lanes 4 and 10). Lane 6 represents a reaction using commercial CK1
(New England BioLabs), and lane 5 shows a control (no enzyme).
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C terminus (DC18) of PfCK1 was found to retain 80% of the
wild type activity. Essentially similar results were obtained
when the DC18 mutant (Fig. 8, lane 6) had a His fusion at the
N terminus. However, deletion of 36 residues from the C ter-
minus, which resulted in the loss of the invariant DW, pro-
duced an essentially inactive enzyme. Deletion of only 8 resi-
dues from the N terminus also resulted in loss of activity,
although an invariant Gly in this region is replaced with an Ala
in PfCK1 (Fig. 1). Kinetic parameters of these two truncated
enzymes, viz. DN8 and DC36, revealed an appreciable defect in
their interaction with Mg-ATP and a greater defect in Kcat
(Table I), thus defining the boundaries of a minimal CK1 cat-
alytic core and confirming that the CKi1D298 of S. pombe was
indeed close to this limit (5, 6).
DISCUSSION
In this paper, we have identified the PfCK1 gene and enzyme
in the malaria parasite P. falciparum. We have also confirmed
the roles of some of the conserved residues of PfCK1 through
site-directed mutational studies and analyzed the parasite
stage-specific expression of PfCK1 transcripts and its enzy-
matic activity. The native as well as the recombinant enzyme
synthesized in E. coli showed properties diagnostic of CK1.
Deletion analysis of PfCK1 (Table I) strongly suggested a role
of the terminal regions outside the conserved catalytic core in
modulating enzyme activity. Curiously, in the crystal struc-
ture, neither of these regions was predicted to be directly in-
volved in either Mg-ATP binding or catalytic function (6). Thus,
we presume that these terminal sequences may somehow in-
fluence the overall conformation of the enzyme or its active site.
Nevertheless, these deletions helped us define the boundaries
of the minimal catalytic core of CK1. To our knowledge, the
324-amino acid-long malarial CK1 enzyme reported here is one
of the shortest naturally occurring CK1 and contains only 34
residues following the invariant DW dipeptide (Fig. 1). In this
regard, it is comparable with, albeit slightly smaller than, the
CK1 a and b isoforms of higher eukaryotes, the shortest of
which is bovine CK1a, containing 325 amino acids (24). This
probably underscores the more primitive evolutionary status of
this obligatory parasite compared with its eukaryotic hosts. On
a similar note, PPl, a prokaryotic protein phosphatase, was
recently been shown to contain very little sequence information
beyond the conserved domains and, thus, appeared to be equiv-
alent to the minimal catalytic core of the larger eukaryotic
phosphatases (16).
Primarily through the analysis of deletion mutants, the C-
terminal tail beyond the conserved region of CK1 has been
postulated to be involved in a number of regulatory mecha-
nisms, viz. autophosphorylation, autoinhibition, membrane lo-
calization, and heparin-mediated activation (Fig. 4) of CK1
activity, some of which may be interrelated (5, 17). In this
respect, the PfCK1 enzyme also appears to be unique. First, it
is in fact shorter than all CK1a isoforms and is still activated
by heparin. Second, the short C terminus of PfCK1 has very
little homology with other CK1 isoforms (Fig. 1). Third, in
preliminary studies, PfCK1 did not exhibit any appreciable
autophosphorylation (data not shown), suggesting that this
may not be required for heparin activation of PfCK1. Finally,
we did not get any C-terminal deletions of PfCK1 that exhibited
higher activity than the full-length enzyme. The shortest dele-
tion tested (DC18) actually lost about 20% activity but at the
same time also lost heparin activation (data not shown). Thus,
it appears that the malarial enzyme is unique in that it lacks
autophosphorylation and autoinhibition but still retains hepa-
rin activation, which most likely maps within the last 18 resi-
dues of the C terminus. Perhaps heparin-activation requires a
certain conformation in the C terminus that is attained
through phosphorylation in other CK1 isoforms but is consti-
tutively present in PfCK1. The significance of the potential
regulation of PfCK1 by heparin in the parasitic life cycle awaits
further study. Since the C-terminal region has been implicated
in targeting the enzyme to the membranes (25), it will be
interesting to determine whether malarial CK1 is primarily
localized in the cytosolic compartment of the parasitic cell.
CK1 enzymes in general are known to require acidic residues
(Asp or Glu) on the N-terminal side of the phosphorylatable Ser
in the substrate, especially in the n-3 position, where the Ser is
at position n; however, a phosphorylated residue at n-3 results
in a pronouncedly higher Kcat:Km ratio (26, 27). With either
recombinant or native PfCK1, we have also seen pronouncedly
better phosphorylation of the peptide substrate KRRRALpS-
VASLPGL than the nonphosphorylated D4 peptide (Promega).
This prompted us to use native casein that has not been de-
phosphorylated as the substrate for the CK1 assay in vitro. In
our SDS-PAGE analysis, commercial casein migrated in three
bands: a faster, major band and two minor, slower migrating
ones. Malarial CK1 phosphorylated the slowest migrating band
much more efficiently (Figs. 3 and 9), while CK2 preferentially
phosphorylated the faster migrating one (Fig. 9). Commercially
obtained recombinant CK1d also resembled malarial CK1 in
this respect (data not shown). Although we do not know the
exact reason behind it, we speculate that the slower species
may represent the more highly phosphorylated forms of casein
and, thus, function as better substrates for CK1.
Several characteristics of the PfCK1 described here are rem-
iniscent of a protein kinase activity previously described in
partially purified cytosolic fractions of Plasmodium (28–30). In
brief, the activity phosphorylated casein as well as phosvitin,
required Mg21, preferred ATP over GTP, was stimulated by
polyamines spermine and spermidine, and was inhibited by the
flavone, quercitin. It also appeared that trophozoites possessed
higher amounts of this activity than either the ring or schizont
stages (30), which is similar to the stage-specific variation of
PfCK1 activity that we have observed (Figs. 6 and 7). What is
intriguing, however, is the apparent lack of correlation of the
relative steady state levels of PfCK1 mRNA (Fig. 5) and en-
zyme activities (Fig. 6) in the various stages of Plasmodium.
The schizonts, for example, have at least twice as much CK1
mRNA as the trophozoites; however, the schizonts possessed
negligible amounts of CK1 activity, whereas the trophozoites
exhibited the highest activity of all three stages. It is thus
tempting to speculate that the Plasmodium CK1 expression
undergoes stage-specific regulation at transcriptional as well
as post-transcriptional levels. A distinction between transla-
TABLE I
Kinetic parameters of mutant PfCK1 enzymes
Kinase reactions using casein as substrate and the determination of
Km and Kcat were carried out as described under “Experimental Proce-
dures.” All CK1 enzymes used in this experiment were expressed from
the pET-3a vector and were devoid of any exogenous sequence, viz the
His6 fusion peptide. DC18 had near normal activity and, therefore, was
not studied in detail. S.D. values were calculated from three independ-
ent measurements.
Enzyme Km of Mg
21 Km of ATP Kcat
mM mM s21 3 100
Wild type 12 6 1 14 6 1.5 1550 6 170
K38L 1450 6 130 2240 6 150 12 6 2
K130L 1235 6 120 2500 6 210 8 6 1
D151N 1125 6 90 1250 6 110 10 6 2
N133A 2250 6 180 1125 6 102 11 6 2
G21A 15 6 1.8 150 6 12 72 6 10
DC36 21 6 2 25 6 2 124 6 11
DN8 32 6 2 40 6 3 115 6 10
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tional and post-translation regulations will ideally require the
use of a specific anti-PfCK1 antibody, which is currently
unavailable.
The CK1 family of enzymes phosphorylates a variety of phys-
iological substrates including transcription factor CREM (31),
glycogen synthase (32), p53 (33), and the SV40 T antigen (34).
Individual CK1 isoforms in lower eukaryotes are found in the
cytoplasm as well as in the nuclei and play essential roles in
the regulation of cellular morphogenesis and DNA repair (35–
37). Self-phosphorylation of malarial cytoplasmic extracts re-
vealed a number of phosphoproteins (Refs. 29 and 30; Fig. 7) of
unknown identity. The unique phosphoprotein profile in the
schizont stage (Fig. 7) was most easily explained by the exceed-
ingly low CK1 activity in this stage compared with the others
(Fig. 6) and by the fact that the addition of exogenous CK1
made the schizont profile resemble those of the other two
stages (Fig. 7). However, the possibility that some substrate
proteins themselves may also undergo stage-specific expression
has been suggested (30) and merits further investigation for its
obvious regulatory implications. In recent years, Plasmodium
infection of human red blood cells was shown to result in
elevated phosphorylation of a number of human red blood cell
membrane proteins (38–41). This included protein 4.1, a 80-
kDa polypeptide, the phosphorylation of which was enhanced
in the trophozoite-schizont stage of infection, and appeared to
involve a casein kinase activity (40). Although additional stud-
ies are needed to ascertain the exact nature of the kinase(s),
this result raises the exciting possibility that the malarial CK1
may in fact modulate host-parasite interactions, which will
have important consequences in the prevention and manage-
ment of malaria. In any case, the demonstration of the CK1
gene and enzyme in P. falciparum and their regulation in the
various stages of the protozoan life cycle should open up new
directions of research in the signal transduction pathways of
this clinically important parasite.
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